

# Lisa Stamp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7246976/publications.pdf>

Version: 2024-02-01

181  
papers

6,597  
citations

76326

40  
h-index

82547

72  
g-index

184  
all docs

184  
docs citations

184  
times ranked

6749  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
2	Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. <i>Lancet Rheumatology, The</i> , 2022, 4, e53-e60.	3.9	18
3	Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. <i>Lancet Rheumatology, The</i> , 2022, 4, e274-e281.	3.9	19
4	Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2022, 175, 461-470.	3.9	17
5	Is repeat serum urate testing superior to a single test to predict incident gout over time?. <i>PLoS ONE</i> , 2022, 17, e0263175.	2.5	0
6	Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1059-1069.	5.6	15
7	Plasma interleukin-23 and circulating IL-17A+IFN $\gamma$ + ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 57.	3.5	9
8	Self-management of gout using a mobile app. <i>Lancet Rheumatology, The</i> , 2022, 4, e304-e305.	3.9	0
9	Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomes—protocol for a population-based retrospective study. <i>BMJ Open</i> , 2022, 12, e050934.	1.9	2
10	A Polynesian-specific copy number variant encompassing the MICA gene associates with gout. <i>Human Molecular Genetics</i> , 2022, 31, 3757-3768.	2.9	3
11	Effect of omega-three supplementation on serum urate and gout flares in people with gout; a pilot randomized trial. <i>BMC Rheumatology</i> , 2022, 6, .	1.6	4
12	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. <i>Journal of Rheumatology</i> , 2021, 48, 293-298.	2.0	11
13	Which factors predict discordance between a patient and physician on a gout flare?. <i>Rheumatology</i> , 2021, 60, 773-779.	1.9	5
14	Trans-ancestral dissection of urate- and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects. <i>Journal of Human Genetics</i> , 2021, 66, 161-169.	2.3	6
15	Variability in Urate-lowering Therapy Prescribing: A Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey. <i>Journal of Rheumatology</i> , 2021, 48, 152-153.	2.0	5
16	What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. <i>Patient</i> , 2021, 14, 505-532.	2.7	2
17	What is remission in gout and how should we measure it?. <i>Rheumatology</i> , 2021, 60, 1007-1009.	1.9	4
18	Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110280.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Impact of COVID-19 on health research in New Zealand: a case study of a research-intensive campus. <i>Journal of the Royal Society of New Zealand</i> , 2021, 51, S75-S85.	1.9	5
20	Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkaa073.	0.7	8
21	Multi-energy photon-counting computed tomography versus other clinical imaging techniques for the identification of articular calcium crystal deposition. <i>Rheumatology</i> , 2021, 60, 2483-2485.	1.9	20
22	Nortriptyline for pain in knee osteoarthritis: a double-blind randomised controlled trial in New Zealand general practice. <i>British Journal of General Practice</i> , 2021, 71, e538-e546.	1.4	6
23	The comparative effect of exposure to various risk factors on the risk of hyperuricaemia: diet has a weak causal effect. <i>Arthritis Research and Therapy</i> , 2021, 23, 75.	3.5	19
24	Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 721-724.	5.6	10
25	Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. <i>Arthritis Research and Therapy</i> , 2021, 23, 130.	3.5	23
26	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. <i>ACR Open Rheumatology</i> , 2021, 3, 333-340.	2.1	37
27	Elevated Urate Levels Do Not Alter Bone Turnover Markers: Randomized Controlled Trial of Inosine Supplementation in Postmenopausal Women. <i>Arthritis and Rheumatology</i> , 2021, 73, 1758-1764.	5.6	5
28	Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. <i>Nature Reviews Rheumatology</i> , 2021, 17, 633-641.	8.0	36
29	Aotearoa New Zealand Māori and Pacific Population-amplified Gout Risk Variants: <i>CLNK</i> Is a Separate Risk Gene at the <i>SLC2A9</i> Locus. <i>Journal of Rheumatology</i> , 2021, 48, 1736-1744.	2.0	8
30	Longitudinal development of incident gout from low-normal baseline serum urate concentrations: individual participant data analysis. <i>BMC Rheumatology</i> , 2021, 5, 33.	1.6	0
31	Assessing the Relationship Between Serum Urate and Urolithiasis Using Mendelian Randomization: An Analysis of the UK Biobank. <i>American Journal of Kidney Diseases</i> , 2021, 78, 210-218.	1.9	8
32	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 946-950.	3.4	11
33	Dual-Energy Computed Tomography for Detection and Characterization of Monosodium Urate, Calcium Pyrophosphate, and Hydroxyapatite. <i>Investigative Radiology</i> , 2021, 56, 417-424.	6.2	17
34	Treatment advances in gout. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101719.	3.3	12
35	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1378-1385.	3.4	3
36	Development of a radiographic scoring system for new bone formation in gout. <i>Arthritis Research and Therapy</i> , 2021, 23, 296.	3.5	0

#	ARTICLE	IF	CITATIONS
37	The Māori and Pacific specific CREBRF variant and adult height. <i>International Journal of Obesity</i> , 2020, 44, 748-752.	3.4	15
38	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urateâ€Lowering Responseâ€”In Search of a Minimum Effective Oxypurinol Concentration. <i>Clinical and Translational Science</i> , 2020, 13, 110-115.	3.1	6
39	Lack of effect of tart cherry concentrate dose on serum urate in people with gout. <i>Rheumatology</i> , 2020, 59, 2374-2380.	1.9	14
40	Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives. <i>Patient</i> , 2020, 13, 225-234.	2.7	12
41	Do Serum Urateâ€Associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank. <i>Arthritis and Rheumatology</i> , 2020, 72, 1184-1191.	5.6	10
42	Formation of the Australian and New Zealand Vasculitis Society (ANZVASC) to improve the care of patients with vasculitis in Australia and New Zealand. <i>Internal Medicine Journal</i> , 2020, 50, 781-783.	0.8	3
43	Effect of body mass index on serum urate and renal uric acid handling responses to an oral inosine load: experimental intervention study in healthy volunteers. <i>Arthritis Research and Therapy</i> , 2020, 22, 259.	3.5	11
44	The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion. <i>Nature Communications</i> , 2020, 11, 2767.	12.8	71
45	The contribution from interleukin-27 towards rheumatoid inflammation: insights from gene expression. <i>Genes and Immunity</i> , 2020, 21, 249-259.	4.1	7
46	Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 536-544.	0.9	44
47	Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout. <i>Arthritis Research and Therapy</i> , 2020, 22, 45.	3.5	28
48	Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. <i>Rheumatology</i> , 2020, 59, 2544-2549.	1.9	30
49	Allopurinol hypersensitivity: Pathogenesis and prevention. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101501.	3.3	23
50	Do Serum Urateâ€associated Genetic Variants Influence Gout Risk in People Taking Diuretics? Analysis of the UK Biobank. <i>Journal of Rheumatology</i> , 2020, 47, 1704-1711.	2.0	2
51	Infliximab and adalimumab concentrations and antiâ€drug antibodies in inflammatory bowel disease control using New Zealand assays. <i>Internal Medicine Journal</i> , 2019, 49, 513-518.	0.8	8
52	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1967-1968.	5.6	0
53	Population-specific factors associated with fractional excretion of uric acid. <i>Arthritis Research and Therapy</i> , 2019, 21, 234.	3.5	11
54	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72

#	ARTICLE	IF	CITATIONS
55	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. <i>Musculoskeletal Care</i> , 2019, 17, 161-169.	1.4	9
56	Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 1733-1738.	5.6	23
57	Winds of change in imaging of calcium crystal deposition diseases. <i>Joint Bone Spine</i> , 2019, 86, 665-668.	1.6	15
58	Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1739-1746.	5.6	64
59	A Pilot Randomized Controlled Double-Blind Trial of High- Versus Low-Dose Weekly Folic Acid in People With Rheumatoid Arthritis Receiving Methotrexate. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 284-287.	0.9	4
60	Clinical Utility of Multi-Energy Spectral Photon-Counting Computed Tomography in Crystal Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1158-1162.	5.6	65
61	Gout. <i>Nature Reviews Disease Primers</i> , 2019, 5, 69.	30.5	326
62	No association between <i>ATP-binding cassette transporter G2</i> rs2231142 (Q141K) and urate-lowering response to febuxostat. <i>Rheumatology</i> , 2019, 58, 547-548.	1.9	6
63	Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1378-1379.	2.4	5
64	Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study. <i>Internal Medicine Journal</i> , 2019, 49, 838-842.	0.8	6
65	Interactions between serum urate-associated genetic variants and sex on gout risk: analysis of the UK Biobank. <i>Arthritis Research and Therapy</i> , 2019, 21, 13.	3.5	19
66	Prevention and treatment of gout. <i>Nature Reviews Rheumatology</i> , 2019, 15, 68-70.	8.0	23
67	Association between ABCG2 rs2231142 and poor response to allopurinol: replication and meta-analysis. <i>Rheumatology</i> , 2018, 57, 656-660.	1.9	34
68	The impact of diuretic use and <i>ABCG2</i> genotype on the predictive performance of a published allopurinol dosing tool. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 937-943.	2.4	11
69	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. <i>Journal of Rheumatology</i> , 2018, 45, 419-424.	2.0	15
70	Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 571-578.	0.9	30
71	How to prevent allopurinol hypersensitivity reactions?. <i>Rheumatology</i> , 2018, 57, i35-i41.	1.9	43
72	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 293-301.	3.4	32

#	ARTICLE	IF	CITATIONS
73	Plasma oxypurinol as a measure of adherence in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 313-314.	0.9	9
74	Lack of Evidence that Soluble Urate Directly Influences Bone Remodelling: A Laboratory and Clinical Study. <i>Calcified Tissue International</i> , 2018, 102, 73-84.	3.1	4
75	An association of smoking with serum urate and gout: A health paradox. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 825-842.	3.4	27
76	Reconceptualizing motivation for smoking cessation among people with rheumatoid arthritis as incentives and facilitators. <i>Musculoskeletal Care</i> , 2018, 16, 139-146.	1.4	7
77	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 462-467.	5.6	68
78	Exploring perceptions of a rheumatoid arthritis-specific smoking cessation programme. <i>Musculoskeletal Care</i> , 2018, 16, 74-81.	1.4	7
79	Improving gout education from patients' perspectives: a focus group study of Māori and Pākehā people with gout. <i>Journal of Primary Health Care</i> , 2018, 10, 194.	0.6	9
80	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. <i>Arthritis Research and Therapy</i> , 2018, 20, 255.	3.5	9
81	Conjugation of urate-derived electrophiles to proteins during normal metabolism and inflammation. <i>Journal of Biological Chemistry</i> , 2018, 293, 19886-19898.	3.4	10
82	ABCG2 rs2231142 (Q141K) and oxypurinol concentrations in people with gout receiving allopurinol. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 241-242.	2.2	7
83	Expert opinion on emerging urate-lowering therapies. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 201-209.	2.4	22
84	Mediation analysis to understand genetic relationships between habitual coffee intake and gout. <i>Arthritis Research and Therapy</i> , 2018, 20, 135.	3.5	16
85	Re: "Widespread prevalence of a CREBRF variant among Māori and Pacific children is associated with weight and height in early childhood". <i>International Journal of Obesity</i> , 2018, 42, 1389-1391.	3.4	5
86	Multiplexed Nanopore Sequencing of HLA-B Locus in Māori and Pacific Island Samples. <i>Frontiers in Genetics</i> , 2018, 9, 152.	2.3	17
87	Greenshell's Mussels: A Review of Veterinary Trials and Future Research Directions. <i>Veterinary Sciences</i> , 2018, 5, 36.	1.7	9
88	Discordant association of the CREBRF rs373863828 A allele with increased BMI and protection from type 2 diabetes in Māori and Pacific (Polynesian) people living in Aotearoa/New Zealand. <i>Diabetologia</i> , 2018, 61, 1603-1613.	6.3	61
89	The relationship between ferritin and urate levels and risk of gout. <i>Arthritis Research and Therapy</i> , 2018, 20, 179.	3.5	23
90	Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial. <i>Rheumatology</i> , 2018, 57, 2183-2189.	1.9	6

#	ARTICLE	IF	CITATIONS
91	Co-expression of CD21L and IL17A defines a subset of rheumatoid synovia, characterised by large lymphoid aggregates and high inflammation. <i>PLoS ONE</i> , 2018, 13, e0202135.	2.5	6
92	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. <i>Arthritis and Rheumatology</i> , 2018, 70, 1702-1709.	5.6	86
93	Association of Crohn's disease-related chromosome 1q32 with ankylosing spondylitis is independent of bowel symptoms and faecal calprotectin. <i>PeerJ</i> , 2018, 6, e5088.	2.0	4
94	Hydrogen sulfide acts as a pro-inflammatory mediator in rheumatic disease. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 182-189.	1.9	31
95	Efficacy of a Rheumatoid Arthritis-Specific Smoking Cessation Program: A Randomized Controlled Pilot Trial. <i>Arthritis Care and Research</i> , 2017, 69, 28-37.	3.4	24
96	Renal dosing of allopurinol results in suboptimal gout care. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e1-e1.	0.9	9
97	Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study. <i>RMD Open</i> , 2017, 3, e000424.	3.8	3
98	Individualising the dose of allopurinol in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2015-2026.	2.4	17
99	Population-specific Resequencing Associates the ATP-binding Cassette Subfamily C Member 4 Gene With Gout in New Zealand Māori and Pacific Men. <i>Arthritis and Rheumatology</i> , 2017, 69, 1461-1469.	5.6	46
100	Population-specific association between ABCG2 variants and tophaceous disease in people with gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 43.	3.5	25
101	A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1522-1528.	0.9	107
102	Fructose malabsorption in people with and without gout: A case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 257-263.	3.4	1
103	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 869-877.	0.9	114
104	Rates of Joint Replacement Surgery in New Zealand, 1999-2015: A Comparison of Rheumatoid Arthritis and Osteoarthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1823-1827.	2.0	8
105	Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2065-2070.	0.9	53
106	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
107	Management of Gout in a Hospital Setting: A Lost Opportunity. <i>Journal of Rheumatology</i> , 2017, 44, 1493-1498.	2.0	10
108	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). <i>Nature Reviews Rheumatology</i> , 2017, 13, 561-568.	8.0	74

#	ARTICLE	IF	CITATIONS
109	Digital-PCR for gene expression: impact from inherent tissue RNA degradation. <i>Scientific Reports</i> , 2017, 7, 17235.	3.3	17
110	Major unanswered questions in the clinical gout field. <i>Current Opinion in Rheumatology</i> , 2017, 29, 171-177.	4.3	6
111	The genetics of gout: towards personalised medicine?. <i>BMC Medicine</i> , 2017, 15, 108.	5.5	44
112	Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 457-464.	3.4	48
113	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 71-78.	1.9	14
114	The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial. <i>Arthritis Research and Therapy</i> , 2017, 19, 283.	3.5	24
115	Interaction of the GCKR and A1CF loci with alcohol consumption to influence the risk of gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 161.	3.5	29
116	Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 241.	3.5	3
117	Expression of the genes facilitating methotrexate action within subcutaneous rheumatoid nodules. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 943-947.	0.8	6
118	Performance of classification criteria for gout in early and established disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 178-182.	0.9	36
119	Urate crystal deposition and bone erosion in gout: "inside-out" or "outside-in"? A dual-energy computed tomography study. <i>Arthritis Research and Therapy</i> , 2016, 18, 208.	3.5	33
120	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	3.4	48
121	Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard. <i>Arthritis Care and Research</i> , 2016, 68, 1894-1898.	3.4	34
122	Predicting allopurinol response in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 277-289.	2.4	46
123	Gout. <i>Lancet</i> , The, 2016, 388, 2039-2052.	13.7	774
124	Clinical and genetic features of diuretic-associated gout: a case-control study. <i>Rheumatology</i> , 2016, 55, 1172-1176.	1.9	5
125	Replication of association of the apolipoprotein A1-C3-A4 gene cluster with the risk of gout. <i>Rheumatology</i> , 2016, 55, 1421-1430.	1.9	16
126	Allopurinol Dose Reductions Based on Creatinine Alert Redesign System. <i>American Journal of Medicine</i> , 2016, 129, e95.	1.5	1



#	ARTICLE	IF	CITATIONS
127	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. <i>BMJ Open</i> , 2016, 6, e012026.	1.9	5
128	Lack of direct evidence for natural selection at the candidate thrifty gene locus, PPARGC1A. <i>BMC Medical Genetics</i> , 2016, 17, 80.	2.1	10
129	Association analysis of the beta-3 adrenergic receptor Trp64Arg (rs4994) polymorphism with urate and gout. <i>Rheumatology International</i> , 2016, 36, 255-261.	3.0	10
130	Allopurinol et fonction rénale. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 328-333.	0.0	0
131	Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated. <i>Journal of Rheumatology</i> , 2016, 43, 150-153.	2.0	25
132	Developing a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients. <i>Musculoskeletal Care</i> , 2016, 14, 2-14.	1.4	11
133	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1363-1366.	0.9	30
134	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. <i>Nature Reviews Rheumatology</i> , 2016, 12, 235-242.	8.0	139
135	Allopurinol and kidney function: An update. <i>Joint Bone Spine</i> , 2016, 83, 19-24.	1.6	31
136	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. <i>PLoS ONE</i> , 2016, 11, e0147939.	2.5	31
137	Nortriptyline in knee osteoarthritis (NortIKA Study): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 448.	1.6	5
138	Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. <i>Arthritis Research and Therapy</i> , 2015, 17, 333.	3.5	14
139	Association of SLC2A9 genotype with phenotypic variability of serum urate in pre-menopausal women. <i>Frontiers in Genetics</i> , 2015, 6, 313.	2.3	16
140	Sugar Sweetened Beverage Consumption among Adults with Gout or Type 2 Diabetes. <i>PLoS ONE</i> , 2015, 10, e0125543.	2.5	10
141	Patient Information about Gout: An International Review of Existing Educational Resources. <i>Journal of Rheumatology</i> , 2015, 42, 975-978.	2.0	20
142	Native Joint Septic Arthritis: Epidemiology, Clinical Features, and Microbiological Causes in a New Zealand Population. <i>Journal of Rheumatology</i> , 2015, 42, 2392-2397.	2.0	75
143	Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 908-911.	0.9	184
144	Why compare the effectiveness of suboptimal gout management?. <i>Nature Reviews Rheumatology</i> , 2015, 11, 506-507.	8.0	9

#	ARTICLE	IF	CITATIONS
145	Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 196.	1.9	27
146	Body mass index modulates the relationship of sugar-sweetened beverage intake with serum urate concentrations and gout. <i>Arthritis Research and Therapy</i> , 2015, 17, 263.	3.5	24
147	Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. <i>Arthritis Research and Therapy</i> , 2015, 17, 288.	3.5	54
148	Simplification of a pharmacokinetic model for red blood cell methotrexate disposition. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1509-1516.	1.9	4
149	Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2144-2150.	0.9	19
150	Modulation of Genetic Associations with Serum Urate Levels by Body-Mass-Index in Humans. <i>PLoS ONE</i> , 2015, 10, e0119752.	2.5	64
151	Safety profile of anti-gout agents. <i>Current Opinion in Rheumatology</i> , 2014, 26, 162-168.	4.3	32
152	Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia. <i>Rheumatology</i> , 2014, 53, 1958-1965.	1.9	35
153	Impaired response or insufficient dosage?â€”Examining the potential causes of â€œinadequate responseâ€”to allopurinol in the treatment of gout. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 170-174.	3.4	43
154	Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. <i>Joint Bone Spine</i> , 2014, 81, 160-163.	1.6	8
155	Sugar-sweetened beverage consumption: a risk factor for prevalent gout with <i>SLC2A9</i> genotype-specific effects on serum urate and risk of gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2101-2106.	0.9	77
156	Screening for hyperuricaemia and gout: a perspective and research agenda. <i>Nature Reviews Rheumatology</i> , 2014, 10, 752-756.	8.0	19
157	Urate-Lowering Therapy: Current Options and Future Prospects for Elderly Patients with Gout. <i>Drugs and Aging</i> , 2014, 31, 777-786.	2.7	20
158	Molecular mechanism of an adverse drugâ€”drug interaction of allopurinol and furosemide in gout treatment. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 157-162.	2.1	22
159	Hyperuricaemia and gout: time for a new staging system?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1598-1600.	0.9	118
160	Expression of Methotrexate Transporters and Metabolizing Enzymes in Rheumatoid Synovial Tissue. <i>Journal of Rheumatology</i> , 2013, 40, 1519-1522.	2.0	14
161	Clinically Insignificant Effect of Supplemental Vitamin C on Serum Urate in Patients With Gout: A Pilot Randomized Controlled Trial. <i>Arthritis and Rheumatism</i> , 2013, 65, 1636-1642.	6.7	68
162	Gout and its comorbidities: implications for therapy. <i>Rheumatology</i> , 2013, 52, 34-44.	1.9	72

#	ARTICLE	IF	CITATIONS
163	Furosemide increases plasma oxypurinol without lowering serum urate—a complex drug interaction: implications for clinical practice. <i>Rheumatology</i> , 2012, 51, 1670-1676.	1.9	38
164	Myeloperoxidase and oxidative stress in rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, 1796-1803.	1.9	180
165	Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. <i>Arthritis Research and Therapy</i> , 2012, 14, R138.	3.5	49
166	Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. <i>Arthritis and Rheumatism</i> , 2012, 64, 2529-2536.	6.7	230
167	Gout and Organ Transplantation. <i>Current Rheumatology Reports</i> , 2012, 14, 165-172.	4.7	13
168	The Christchurch earthquake—providing a rheumatology service during a natural disaster. <i>Clinical Rheumatology</i> , 2012, 31, 723-725.	2.2	3
169	Serum Urate as a Soluble Biomarker in Chronic Gout—Evidence that Serum Urate Fulfills the OMERACT Validation Criteria for Soluble Biomarkers. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 483-500.	3.4	45
170	Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials. <i>Journal of Rheumatology</i> , 2011, 38, 1467-1470.	2.0	23
171	Effects of Changing from Oral to Subcutaneous Methotrexate on Red Blood Cell Methotrexate Polyglutamate Concentrations and Disease Activity in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2540-2547.	2.0	54
172	Serum Urate in Chronic Gout—Will It Be the First Validated Soluble Biomarker in Rheumatology?. <i>Journal of Rheumatology</i> , 2011, 38, 1462-1466.	2.0	17
173	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 367-376.	1.5	57
174	A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets. <i>Human Molecular Genetics</i> , 2010, 19, 4813-4819.	2.9	100
175	Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 2403-2408.	2.0	41
176	Pulmonary haemorrhage in a 13-year-old girl: An unusual presentation of systemic lupus erythematosus. <i>Journal of Paediatrics and Child Health</i> , 2008, 44, 743-745.	0.8	2
177	The use of low dose methotrexate in rheumatoid arthritis—are we entering a new era of therapeutic drug monitoring and pharmacogenomics?. <i>Biomedicine and Pharmacotherapy</i> , 2006, 60, 678-687.	5.6	46
178	Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. <i>Journal of Rheumatology</i> , 2006, 33, 1646-50.	2.0	160
179	Diet and Rheumatoid Arthritis: A Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 77-94.	3.4	121
180	Gout in Solid Organ Transplantation. <i>Drugs</i> , 2005, 65, 2593-2611.	10.9	64

#	ARTICLE	IF	CITATIONS
181	HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab. Journal of Rheumatology, 2005, 32, 382-5.	2.0	2